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Abstract
Background: Factor XIII plays an important role in the stabilization of the linkage between fibrins and 
in the pathophysiology of coronary artery disease (CAD). The association between factor XIII Val34Leu 
polymorphism and CAD risk remains controversial.
Methods: We conducted a meta-analysis of 36 studies involving 26,940 cases and 34,694 controls. 
Subgroup analyses were performed with division of data into disease (myocardial infarction [MI], CAD 
without MI), age, and sex.
Results: Factor XIII Val34Leu polymorphism was significantly associated with ove all CAD risk (odds 
ratio [OR] = 1.09, 95% confidence interval [CI] = 1.03–1.06, p = 0.004) and MI risk (OR = 1.15, 
95% CI 1.07–1.25, p = 0.0003), but not with CAD without MI risk (OR = 1.00, 95% CI 0.87–1.15, 
p = 0.96). In the subgroup analysis by age and sex, there was no association between Val34Leu poly-
morphism and CAD. 
Conclusions: This meta-analysis found that factor XIII Val34Leu polymorphism was associa ted with 
CAD risk, especially MI, but not with CAD without MI. In addition, age and sex did not affect the re-
lationship between factor XIII Val34Leu polymorphism and CAD risk. (Cardiol J 2017; 24, 1: 74–84)
Key words: factor XIII A Val34Leu, coagulation, coronary artery disease,  
myocardial infarction, meta-analysis
Introduction
Coronary artery disease (CAD) is the leading 
cause of death worldwide. Approximately 85.6 mil-
lion American adults suffer from coronary vascular 
disease and around 30% of all deaths in 2013 were 
caused by CAD [1]. Although CAD mortality has 
decreased in recent years, it still remains high. 
CAD is a multifactorial disease with a complex 
pathophysiology generated by the combined ef-
fects of genes and the environment. Improvement 
of environmental factors can reduce the rate of 
CAD prevalence and mortality, but genetic factors 
remain a problem in CAD. A number of genetic risk 
factors have been found to predispose individuals 
to CAD, and the coagulation factor XIII gene, factor 
XIII, has been extensively studied.
Factor XIII plays an important role in the 
stabilization of linkages between fibrins and in the 
pathophysiology of CAD [2, 3]. Factor XIII consists 
of two types of subunits (A2 and B2). Factor XIII-A 
consists of two active A subunits, and factor XIII-B 
consists of inhibitory/carrier B subunits. Factor 
XIII-A, which shows transglutaminase activity, 
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strengthens fibrin polymers and protects them from 
degradation by the fibrinolytic machinery [4]. Many 
studies have investigated the association between 
factor XIII-A gene polymorphisms and susceptibil-
ity to CAD, especially myocardial infarction (MI). 
Most studies have focused on one single-nucleotide 
polymorphism (SNP), which was Val34Leu.
In 2014, two meta-analytical studies were 
published on the association between factor XIII 
Val34Leu polymorphism and MI. Chen et al. [5] 
analyzed 29 studies and showed that factor XIII 
Val34Leu polymorphism may be associated 
with the risk of MI, and Wang et al. [6] analyzed 
12 studies and showed the same result. However, 
the association between overall CAD and factor XIII 
Val34Leu polymorphism has not been analyzed 
since 2007 [7]. The results of a meta-analysis by 
Voko et al. [7] suggest that factor XIII Val34Leu 
polymorphism also affects susceptibility to CAD. In 
the present study, we performed a meta-analysis of 
all eligible studies to assess the relationship of fac-
tor XIII Val34Leu polymorphism with risk of CAD.
Methods
Identification of eligible studies  
and data extraction
A literature search was performed for stud-
ies examining the association between factor XIII 
Val34Leu and CAD. The PUBMED and EMBASE 
citation databases were used to identify avail-
able articles in which the factor XIII Val34Leu 
polymorphism was analyzed in patients with CAD 
(up to May 2016). The search terms used were as 
follows: coronary artery disease, myocardial infarc-
tion, angina, ischemic heart disease, factor XIII or 
F13A1, polymorphism, and mutation or variant. 
References in identified studies were also inves-
tigated to identify additional studies not indexed 
by PUBMED or EMBASE. Studies were included 
in this meta-analysis if 1) they were case-control 
studies that determined the distribution of factor 
XIII Val24Leu polymorphism; 2) they contained 
original data; and 3) they provided sufficient data 
to calculate odd ratios (ORs). No restrictions were 
set on race, language, ethnicity, or geographic area. 
We excluded the following: 1) studies with overlap-
ping data; 2) studies in which the number of null 
and wild-type genotypes or alleles could not be 
ascertained; and 3) studies with only an abstract. 
We extracted author, year of publication, ethnicity 
of the study population, demographics, number of 
cases and controls, and allele frequency of factor 
XIII Val34Leu polymorphism.
Statistical analysis
Prior to pooling the studies for meta-analysis, 
the Hardy-Weinberg equilibrium (HWE) was as-
sessed in the control groups of each study. Chi-
square test was used to determine whether the 
observed frequency of genotypes in the control 
population conformed to HWE expectations. 
A two-sided p value > 0.05 was considered consistent 
with the HWE. Statistical analyses were performed 
using Review Manager 5.3 (The Nordic Cochrane 
Center, The Cochrane Collaboration, 2014). We 
performed meta-analyses using 1) allelic contrast, 
2) homozygote contrast, and 3) recessive and 
4) dominant models. The strength of the association 
between factor XIII Val34Leu polymorphism and 
CAD risk was measured by OR and 95% confidence 
interval (CI). Heterogeneity statistics (I²), overall 
effect (Z score), and p value were calculated. The 
effect of heterogeneity was quantified using I², which 
ranges from 0% to 100% and represents the pro-
portion of between-study variability attributable to 
heterogeneity rather than chance [8]. The I² values 
of 25%, 50%, and 75% were nominally considered 
low, moderate, and high estimates, respectively. 
With an I² value < 25% or p value of heterogeneity 
> 0.10, a fixed effect model was selected for Mantel-
-Haenszel statistics. Otherwise, a random-effect 
model was used [9]. A funnel plot test was used 
to assess publication bias and was set at p < 0.10. 
To evaluate disease-, age-, and sex-specific effects, 
subgroup analyses were performed based on disease 
status, age, and sex. Early-onset MI was defined as 
a cardiac event occurring before the age of 45 years.
Results
Studies included in the meta-analysis
Electronic and manual searches identified 
156 applicable studies, and 42 were selected for 
a full-text review based on the title and abstract 
details. Three studies were excluded due to dupli-
cate data, and other three studies were excluded 
because they were meta-analytical studies between 
factor XIII Val24Leu polymorphism and CAD or 
MI. A total of 36 studies met the inclusion crite-
ria, and separate comparisons were considered in 
the present meta-analysis, which included 26,940 
cases and 34,694 controls [2, 10–44] (Table 1). 
There were 25 studies performed in Europe-
an populations, 3 studies in Asian populations, 
6 studies in North American populations, 
1 study in a South American population, and 
1 study in an African population. The present 
meta-analysis included overall CAD including 
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Table 2. Meta-analysis of association between the factor XIII Val34Leu polymorphism and coronary 
artery disease.
Population Number  
of studies
Case Control Test of association Test of heterogeneity
OR 95% CI P Model P I² (%)
Overall 36 26940 34694 1.09 1.03–1.16 0.004 R 0.003 44
MI 31 21168 29932 1.15 1.07–1.25 0.0003 R 0.0001 55
Without MI 9 2678 3164 1.00 0.05–0.96 0.96 F 0.28 18
Under 45 9 8098 9256 1.03 1.96–1.11 0.4 F 0.1 41
Over 45 7 4260 5020 0.90 0.75–1.08 0.25 R 0.08 47
Male 5 4268 5350 1.08 0.94–1.25 0.27 R 0.09 50
Female 6 2114 4954 1.09 0.97–1.24 0.15 F 0.13 41
CI — confidence interval; F — fixed effects model; MI — myocardial infarction; OR — odds ratio; R — random effects model
MI, unstable angina, coronary sclerosis, cardiac 
syndrome X, vasospastic angina, etc. A total of 
9 studies were performed with patients younger 
than 45 years; among these, 2 studies also con-
tained patients older than 45 years. Including these 
2 studies, a total of 8 studies were performed in pa-
tients older than 45 years. Three studies included 
only male patients, 4 studies only females, and all 
other included both sexes. Two study analyses 
were performed separately based on sex.
Meta-analysis of the association between 
factor XIII Val34Leu polymorphism  
and coronary artery disease
A summary of the meta-analysis findings 
concerning associations between factor XIII Val-
34Leu polymorphism and CAD is provided in 
Table 2. The meta-analysis of factor XIII Val34Leu 
polymorphism showed a significant association be-
tween CAD and the Val allele (OR = 1.09, 95% CI 
1.03–1.06, p = 0.004; Fig. 1). A subgroup analysis 
by disease type (with MI or without MI) showed 
a significant association between MI and the Val 
allele (OR = 1.15, 95% CI 1.07–1.25, p = 0.0003; 
Fig. 2). However, no association was found between 
CAD without MI and the Val allele (OR = 1.00, 95% 
CI 0.87–1.15, p = 0.96). In the subgroup analysis by 
age, no association was found in either the younger 
population (OR = 1.03, 95% CI 0.96–1.11, p = 0.4) 
or older population (OR = 0.90, 95% CI 0.75–1.08, 
p = 0.25). In the subgroup analysis by sex, no as-
sociation was found in males (OR = 1.08, 95% CI 
0.94–1.25, p = 0.27) or females (OR = 1.09, 95% 
CI 0.97–1.24, p = 0.15).
We compared the Val/Val genotype and Val/Leu 
+ Leu/Leu genotype in the overall CAD population 
and subgroups. There was a significant association 
between CAD and the Val/Val genotype (OR = 1.11, 
95% CI 1.03–1.19, p = 0.006; Fig. 3). In the sub-
group analysis, there was a significant association 
between MI and the Val/Val genotype in the CAD 
with MI group (OR = 1.18, 95% CI 1.08–1.30, 
p = 0.0003; Fig. 4). However, in the other subgroup 
analyses, there were no associations between dis-
ease and the Val/Val genotype. We also compared 
the Val/Val genotype and the Leu/Leu genotype 
in the overall CAD population and subgroups. 
Comparison of the Val/Val vs. LeuLeu genotypes 
of overall CAD (OR = 1.19, 95% CI 1.03–1.38, 
p = 0.02) and MI (OR = 1.27, 95% CI 1.06–1.52, 
p = 0.009) also showed a significant association, 
however other subgroups showed no associations.
Heterogeneity and publication bias
Some heterogeneity was found in the meta-
analyses of the factor XIII Val34Leu polymorphisms 
(Table 2). For MI risk, there was significant het-
erogeneity in the Val allele (I2= 55%, p = 0.0001; 
Table 3), and the Val/Val vs. Val/Leu + Leu/Leu 
genotype model (I2 = 53%, p = 0.0003; Table 3). 
There was also significant heterogeneity in the Val/ 
/Val vs. Val/Leu + Leu/Leu genotype model in the 
group of subjects older than 45 years (I2 = 67%, 
p = 0.006) and in the Val allele in males (I2 = 50%, 
p = 0.09). All studies included in this meta-analysis 
satisfied the HWE. Publication bias was examined 
by a funnel plot (Fig. 5). The shape of the funnel 
plot was symmetrical, with 18 studies on the left 
side and 18 studies on the right side.
Discussion
In the current meta-analysis, we investigated 
the association between factor XIII Val34Leu 
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polymorphism and CAD risk, including 26,940 
cases and 34,694 controls. We found that the Val 
allele and Val/Val genotype showed increased risk 
of CAD. However, our meta-analyses did not show 
evidence of an association between factor XIII Val-
34Leu polymorphism and CAD in any subgroup 
except MI. These results are in accord with previ-
ous meta-analyses [5–7]. However, Wang et al. [6] 
suggested that factor XIII Val34Leu polymorphism 
was significantly associated with MI risk in the 
subgroup analyses by age and sex.
In the subgroup analysis by disease, the pre-
sent meta-analysis showed that factor XIII Val-
34Leu polymorphism affected MI risk, but did not 
affect risk in CAD without MI, although the CAD 
without MI group was small (9 studies). CAD 
involves damage from plaque accumulating on 
the arterial wall. The buildup of plaque progres-
sively hardens and narrows blood vessels, a pro-
cess known as atherosclerosis [45]. MI, a severe 
complication of CAD, is commonly defined as 
a cardiomyocyte death due to a prolonged ischemia 
and increase in serum cardiac markers, such as 
troponin [46]. Both MI and CAD without MI are 
caused by atherosclerosis, but MI differs from CAD 
without MI in the existence of cardiac necrosis. 
We suspect that factor XIII has a function not only 
in blood coagulation, but also in healing of tissue 
damage.
Blood coagulation factor XIII has a key role 
in the terminal phase of the clotting cascade, 
which contributes to thrombotic events. Factor XII 
is composed of A and B subunits. Factor XIII 
is activated by thrombin proteolytically and, in the 
presence of calcium, dissociation of subunit B [47]. 
Activated factor XIII induces fibrin cross-linking 
via noncovalent binding of fibrin polymers. This 
process finally forms a stable clot that is resistant 
Figure 1. Odds ratio and 95% confidence interval (CI) of individual studies and pooled data for the association between 
the factor XIII Val allele and coronary artery disease (CAD).
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to shear forces and fibrinolysis [48]. The Val34Leu 
polymorphism in factor XIII A subunit is located 
in the activation peptide 3 amino acid residues 
upstream from the thrombin cleavage site [14]. 
The 34Leu variant increases activation rate by 
thrombin, alters fibrin structure in vitro, and influ-
ences fibrin cross-linking in vivo [47]. Compared 
to CAD without MI, a vulnerable plaque is a cruel 
character of MI. Thus, MI can be protected against 
by increases in factor XIII due to the 34Leu variant. 
However, it remains unclear whether the 34Leu 
variant protects against CAD without MI. The 
present meta-analysis also showed no association 
between CAD without MI and factor XIII Val34Leu 
polymorphisms.
In subgroup analyses by age or sex, there 
were no associations between CAD and factor XIII 
Val34Leu polymorphisms. It is possible that 
the influence of factor XIII Val34Leu polymor-
phism on CAD might be confounded by the 
presence of other unidentified causal genes 
Figure 2. Odds ratio and 95% confidence interval (CI) of individual studies and data pooled for the association between 
the factor XIII Val allele and myocardial infarction (MI).
involved in CAD development. Gene-gene in-
teractions should be considered. Fibrinogen 
is an independent predictor of atherosclerotic 
disease including MI [49]. The factor XIII A 
34Val allele is associated with an increase in 
fibrinogen concentrations, as is the fibrinogen 
Aa 312Ala allele. Fibrinogen Aa Thr312Ala 
polymorphism is also associated with fibrinogen 
concentration. High fibrinogen concentrations 
lead to formation of a fibrin clot, which is highly 
thrombogenic [50]. In addition, factor XIII B 
His95Arg polymorphism is associated with devel-
opment of MI when inherited with factor XIII A 
Val34Leu polymorphism. The Arg95 allele re-
duces MI risk in the presence of the Leu34 
allele [33]. Factor II 20210A and factor V leiden 
variants are also associated with MI risk, and 
Tyr2047Phe and Pro564Leu variants in the factor 
XIII A gene are associated atherosclerotic disease 
[18, 30]. Gene-environment interaction should 
also be considered. Fibrinogen concentrations are 
80 www.cardiologyjournal.org
Cardiology Journal 2017, Vol. 24, No. 1
associated with smoking, insulin resistance and 
physical activity [50]. The 34Leu allele is related 
to taking estrogen [48].
In recent years, another aspect of factor XIII 
has been identified in addition to blood coagulation. 
Factor XIII influences wound healing in several 
tissues, including cardiomyocytes, by exerting 
multiple plasma and cellular functions. Moreover, 
the proangiogenic function of factor XIII is directed 
by the interaction of vascular endothelial growth 
factor receptor 2 and integrin aVb3 on the cell 
membrane [51]. Certain studies showed that low 
factor XIIIA level correlated with a poor prognosis 
with regard to MI [52, 53]. Therefore, MI could be 
differently affected by this function of factor XIII 
compared to CAD without MI.
The present meta-analysis has several strengths. 
It included the largest number of studies. Previous 
meta-analyses included primarily Caucasians, how-
ever this meta-analysis contained other ethnicities 
including Asians. In addition, we used real gene 
polymorphism data in the meta-analysis rather than 
adjusted ORs, which could reduce the bias arising 
from adjustment.
Limitations of the study
As with any meta-analysis, there are a number 
of limitations that need to be considered. First, the 
proportion of studies with MI was too large. Among 
36 studies, MI was included in 31 studies, which 
could overestimate the association between gene 
polymorphism and overall CAD. Second, although 
we sought to study gene effects in all ethnic groups, 
the majority of studies were conducted in Caucasian 
populations. Third, each study was not analyzed us-
ing uniform inclusion and exclusion criteria. Each 
Figure 3. Odds ratio and 95% confidence interval (CI) of individual studies and data pooled for the association between 
the factor XIII Val/Val genotype and coronary artery disease (CAD).
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Figure 4. Odds ratio and 95% confidence interval (CI) of individual studies and data pooled for the association between 
the factor XIII Val/Val genotype and myocardial infarction (MI).
Table 3. Meta-analysis of association between the factor XIII Val34Leu polymorphism and myocardial 
infarction.
Test of association Test of heterogeneity
OR 95% CI P Model P I² (%)
V vs. L 1.15 1.07–1.25 0.0003 R 0.0001 55
VV vs. VL+LL 1.18 1.08–1.30 0.0003 R 0.0003 53
VV+VL vs. LL 1.21 1.02–1.43 0.003 R 0.02 39
VV vs. LL 1.27 1.06–1.52 0.009 R 0.009 44
CI — confidence interval; L — factor XIII Leu; OR — odds ratio; R — random effects model; V — factor XIII Val
study also differently defines MI, even though each 
definition of MI was mostly based on ischemic symp-
tom, change of electrocardiography, and elevation of 
cardiac biomarkers. Fourth, in addition to Val34Leu 
polymorphism, the factor XIII A gene includes other 
genetic variants, such as tyr204Phe and Pro564Leu 
[18]. Fifth, due to the lack of the original data of 
the eligible studies, the evaluation of the effects of 
gene-gene or gene-environment interactions was 
limited, as well as the ability to perform subgroup 
analyses by age and sex. Sixth, all included studies 
were retrospective case-control studies, thus, we 
cannot exclude the possibility of undetected bias. 
Finally, publication bias is an important feature of 
meta-analyses, which we attempted to minimize by 
including studies in all languages.
82 www.cardiologyjournal.org
Cardiology Journal 2017, Vol. 24, No. 1
Conclusions
In conclusion, this meta-analysis showed 
that factor XIII Val34Leu polymorphism was as-
sociated with CAD risk, especially with MI, but 
not with CAD without MI. In addition, age or sex 
did not affect the relationship between factor XIII 
Val34Leu polymorphism and CAD risk. However, 
some significant limitations exist in the interpre-
tation of the result and the present meta-analysis 
should be interpreted with caution.
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